The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals
- Registration Number
- NCT06550271
- Lead Sponsor
- AgelessRx
- Brief Summary
This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 67
Inclusion Criteria
- Receive AgelessRx's standard Rapamycin treatment protocol
- Opted to complete at least 1 blood draw at their local Quest Lab
Exclusion Criteria
- Not approved for current AgelessRx standard Rapamycin treatment
- History of uncontrolled disease
- Unable to complete at least 1 blood draw at their local Quest Lab
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Compounded Rapamycin Rapamycin Participants in this group were receiving Compounded Rapamycin (dosages include 5, 10, or 15mg) once per week Generic Rapamycin Rapamycin Participants in this group were receiving Generia Rapamycin (dosages include 2,3,6, or 8mg) once per week
- Primary Outcome Measures
Name Time Method define the relative bioavailability ratio between compounded rapamycin and generic rapamycin 8 months define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
AgelessRx
🇺🇸Ann Arbor, Michigan, United States